Peter A. Prieto, M.D., M.P.H.

A native of New York, Dr. Peter A. Prieto chose to dedicate his life to conquering cancer after losing his father to sarcoma. Dr. Prieto, completed his general surgery residency at Yale University School of Medicine where he took three years off and completed a surgical oncology research fellowship and a one of its kind immunotherapy fellowship in the surgery branch of the National Cancer Institute, National Institutes of Health under the mentorship of Dr. Steven A. Rosenberg where he was co-investigator on numerous clinical trials.

He went on to complete his chief residency at Yale and then completed a two year clinical complex surgical oncology fellowship at the prestigious MD Anderson Cancer Center in Houston, Texas where he spent an additional year doing a post-doctoral research fellowship under the mentorship of Drs. Jennifer A. Wargo and Funda Meric-Bernstam. At MD Anderson Dr. Prieto was instrumental in the development and analysis of a novel phase II trial looking at neoadjuvant targeted therapy in high-risk resectable stage III BRAF mutant melanoma, which has changed the practice in this challenging patient population.

Dr. Prieto is triple board certified in general surgery, complex general surgical oncology and medical quality. As a fully trained tumor immunotherapist and surgical oncologist, he has expertise in the treatment of primary, regionally advanced and metastatic melanoma, soft tissue sarcoma and breast cancer. His research interests and laboratory investigate mechanisms of immune evasion by tumor to targeted and immune checkpoint blockade and prognostic markers of response to immune based therapies including adoptive cell therapy.

In addition to authoring numerous high impact publications, Dr. Prieto is the recipient of several prestigious awards and honors. He frequently presents on topics related to surgical oncology and melanoma at thenational and international levels. Dr. Prieto's personal mission is to treat all of his patients as if they were his own family.

Credentials

Specialties

Complex General Surgical Oncology
Surgical Oncology
Surgery - American Board of Surgery

Education

1999
BA | State University of New York at Stony Brook
Anthropology

2006
MD | St. George's University School of Medicine
Medicine

2006
MPH | St. George's University School of Medicine
Public Health

Post-doctoral Training & Residency

07/01/2014 - 6/30/2017
Fellowship in Complex General Surgical Oncology at University of Texas M D Anderson Cancer Center

07/01/2011 - 06/30/2014
Residency in General Surgery at Yale New Haven Hospital

07/01/2009 - 6/30/2011
Fellowship in Surgical Oncology at National Cancer Institute

07/01/2008 - 06/30/2009
Fellowship in Immunotherapy at National Cancer Institute

07/01/2007 - 06/30/2008
Residency in General Surgery at State University of New York, Upstate Medical University

07/01/2006 - 06/30/2007
Internship in General Surgery at State University of New York, Upstate Medical University

VIEW ALL

Awards

2018
Seymour I. Schwartz Faculty Excellence in Teaching
Sponsor: University of Rochester School of Medicine and Dentistry

2017 - 2018
W. G. Stuber Research Fellowship Grant
Sponsor: University of Rochester Medical Center

2017
Lotzova Excellence in Research Award, Department of Surgical Oncology
Sponsor: University of Texas MD Anderson Cancer Center

2016
Lotzova Excellence in Research Award, Department of Surgical Oncology
Sponsor: University of Texas MD Anderson Cancer Center

2014
Excellence in Junior Resident Teaching Award
Sponsor: Yale School of Medicine

2014
Sam Harvey Award for Most Outstanding Chief Resident in Surgery
Sponsor: Yale School of Medicine

2013
Excellence In Medical Student Teaching Award
Sponsor: Yale School of Medicine

2006
Arnold P. Gold Humanism Honor Society
Sponsor: St. George's University

1994
Research Career for Minority Scholars (RCMS)
Sponsor: SUNY at Stony Brook

VIEW ALL

Publications

Journal Articles

2/2018
Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial." The Lancet. Oncology.. 2018 Feb 0; 19(2):181-193. Epub 2018 Jan 18.

1/5/2018
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients." Science.. 2018 Jan 5; 359(6371):97-103. Epub 2017 Nov 02.

2018
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. "A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma." Oncoimmunology.. 2018 7(5):e1423172. Epub 2018 Feb 01.

VIEW ALL PUBLICATIONS